🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Argun Akçakanat

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-4012-9840
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
3.4Author DataRank

Indexed papers

5in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3
Top 8%
2.7DataRank
Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Papers

Driven by 15 papers — median percentile 0. Top paper: “Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment”.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3
Top 8%
2.7DataRank
Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

NAR Cancer(2022)10.1093/narcan/zcac014
Top 31%
0.652DataRank
Top 31%22 citations

Michael W. Lloyd, Jeffrey W. Grover, Nan Xiao, Sara Seepo, Sai Lakshmi Subramanian +95 more

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4048
N/A
0.510DataRank · unranked
29 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Research Square(2022)10.21203/rs.3.rs-2248209/v1
N/A
0DataRank · unranked
0 citations

Turçin Saridogan, Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca +11 more

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

npj Breast Cancer(2023)10.1038/s41523-023-00573-8
N/A
0DataRank · unranked
29 citations

Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans +8 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Scientific Reports(2023)10.1038/s41598-023-46586-y
N/A
0DataRank · unranked
15 citations

Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott +11 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Figshare(2023)10.1158/1078-0432.22446608.v1
Top 100%
0DataRank
Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Data from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

(2023)10.1158/1078-0432.c.6530036
Top 100%
0DataRank
Top 100%0 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2023)10.1158/1078-0432.22446608
Top 100%
0DataRank
Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0838
N/A
0DataRank · unranked
25 citations

Kurt W. Evans, Bailiang Wang, Ming Zhao, Argun Akçakanat, Maria Gabriela Raso +14 more

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1948
N/A
0DataRank · unranked
22 citations

Erkan Yuca, Kurt W. Evans, Ming Zhao, Takanori Maejima, Tsuyoshi Karibe +12 more

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Oncotarget(2020)10.18632/oncotarget.27503
N/A
0DataRank · unranked
24 citations

Ming Zhao, Argun Akçakanat, Kurt W. Evans, Erkan Yuca, Ecaterina Ileana Dumbrava +3 more

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0884
N/A
0DataRank · unranked
1 citations

Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng +10 more

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Breast Cancer Research(2021)10.1186/s13058-021-01406-x
N/A
0DataRank · unranked
70 citations

Ming Zhao, Erkan Yuca, Allen Annis, Kurt W. Evans, David Sutton +13 more

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Scientific Reports(2022)10.1038/s41598-022-05193-z
N/A
0DataRank · unranked
9 citations

Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen +12 more